Searchable abstracts of presentations at key conferences in endocrinology

ea0022p75 | Bone/Calcium | ECE2010

Structural heart disease in osteogenesis imperfecta: a case–control study

Guardiola Patricia Diaz , Jimenez Vanesa Bonilla , Falero Jesus Saavedra , Vela Maria Teresa Alberca , Bolanos Paloma Iglesias , de Paz Isabel Pavon

Background: Osteogenesis imperfecta (OI) is a few frequent disease with abnormal synthesis of type 1 collagen. That affects skeletal but also extra-skeletal tissues. Aortic root (AR) dilatation and valvular dysfunction have been described. Other studies, to estimate the size of the AR, index it by the body surface area (BSA), however, although these patients are shorter their internal organs have a relatively normal growth, so we could find overestimated AR values. Therefore, ...

ea0056gp11 | Acromegaly | ECE2018

Observational, multicentre study to evaluate the effectiveness in routine clinical practice of Lanreotide Autogel 120 mg at extended dosing intervals (>4 weeks) for the treatment of acromegaly: SOMACROL study

Escola Cristina Alvarez , Fajardo Carmen , Marazuela Monica , Carballido Fernando Cordido , Venegas Eva Maria , Velasco Pedro de Pablos , Maroto Gonzalo Piedrola , Marquez Ma del Pilar Olvera , de Paz Isabel Pavon , Carvalho Davide , Romero Carme , De la Cruz Guillermo , Bernabeu Ignacio

Background: Acromegaly is usually caused by a benign pituitary tumour, with increased production of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Treatment options include surgery, followed by pharmacological treatment with dopamine agonists, somatostatin analogues, GH receptor antagonists or radiotherapy. Treatment optimization is important to decrease the burden of this often-chronic disease on the patient.Objectives: To evaluate the ef...